Achieve Life Sciences is a specialty
pharmaceutical company committed to advancing
cytisinicline as a smoking cessation aid to address
the global tobacco and nicotine addiction
epidemic. Cytisinicline (also known as cytisine) is a
plant-based alkaloid with a high binding affinity to
the α4β2 nicotine receptor.
Growing confidence in a replacement for the
expiring Pfizer anti smoking drug plus a succesful
New Zealand clinical trial have lifted prospects for
Achieve. Institutional holders have increased from
9 to 15 in the December quarter.
29 Apr 2021
DataBrief : Achieve Life Sciences Inc.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
DataBrief : Achieve Life Sciences Inc.
Achieve Life Sciences, Inc. (ACHV:NAS) | 0 0 0.0%
- Published:
29 Apr 2021 -
Author:
Independent Research - Pages:
Achieve Life Sciences is a specialty
pharmaceutical company committed to advancing
cytisinicline as a smoking cessation aid to address
the global tobacco and nicotine addiction
epidemic. Cytisinicline (also known as cytisine) is a
plant-based alkaloid with a high binding affinity to
the α4β2 nicotine receptor.
Growing confidence in a replacement for the
expiring Pfizer anti smoking drug plus a succesful
New Zealand clinical trial have lifted prospects for
Achieve. Institutional holders have increased from
9 to 15 in the December quarter.